APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Peptide Therapeutics Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Peptide Therapeutics Drugs Market Analysis and Forecast 2026-2032

Report ID 174023680223 December 2025200 pages

Choose your research edition.

Industry ResearchPeptide Therapeutics Drugs Industry Research Report 2026128 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Therapeutics Drugs Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Peptide Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Therapeutics Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Therapeutics Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Peptide Therapeutics Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Peptide Therapeutics Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Peptide Therapeutics Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Peptide Therapeutics Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Peptide Therapeutics Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Peptide Therapeutics Drugs include Takeda, Teva, Sanofi, J & J, Novartis, Novo Nordisk, Merck, Eli Lilly and Ferring, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Peptide Therapeutics Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Peptide Therapeutics Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Peptide Therapeutics Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Peptide Therapeutics Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Peptide Therapeutics Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Peptide Therapeutics Drugs revenue, projected growth trends, production technology, application and end-user industry.

Peptide Therapeutics Drugs Segment by Company

Takeda

Teva

Sanofi

J & J

Novartis

Novo Nordisk

Merck

Eli Lilly

Ferring

AbbVie

AstraZeneca

The Medicines

Lantheus

Ipsen

CSL Vifor Group

BioMarin Pharmaceutical

Aurinia Pharmaceuticals

Apellis Pharmaceuticals

Peptide Therapeutics Drugs Segment by Type

Injection

Oral

Other

Peptide Therapeutics Drugs Segment by Application

Central Nervous System

Metabolic Disorders

Cancer

Other

Peptide Therapeutics Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Therapeutics Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Peptide Therapeutics Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Peptide Therapeutics Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Therapeutics Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Peptide Therapeutics Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Player Table 3. Oral Major Player Table 4. Other Major Player Table 5. Global Peptide Therapeutics Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Central Nervous System Major Player Table 7. Metabolic Disorders Major Player Table 8. Cancer Major Player Table 9. Other Major Player Table 10. Peptide Therapeutics Drugs Industry Trends Table 11. Peptide Therapeutics Drugs Industry Drivers Table 12. Peptide Therapeutics Drugs Industry Opportunities and Challenges Table 13. Peptide Therapeutics Drugs Industry Restraints Table 14. Global Peptide Therapeutics Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Peptide Therapeutics Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Peptide Therapeutics Drugs Market Share by Region (2021-2026) Table 17. Global Peptide Therapeutics Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Peptide Therapeutics Drugs Market Share by Region (2027-2032) Table 19. Global Peptide Therapeutics Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Peptide Therapeutics Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Peptide Therapeutics Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Peptide Therapeutics Drugs Key Players Headquarters & Area Served Table 23. Global Peptide Therapeutics Drugs Players, Product Type & Application Table 24. Global Peptide Therapeutics Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Peptide Therapeutics Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Peptide Therapeutics Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Peptide Therapeutics Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Peptide Therapeutics Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Peptide Therapeutics Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Peptide Therapeutics Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Peptide Therapeutics Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Peptide Therapeutics Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Peptide Therapeutics Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Peptide Therapeutics Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Peptide Therapeutics Drugs Revenue Market Share by Application (2027-2032) Table 37. Takeda Company Information Table 38. Takeda Business Overview Table 39. Takeda Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Takeda Peptide Therapeutics Drugs Product Portfolio Table 41. Takeda Recent Development Table 42. Teva Company Information Table 43. Teva Business Overview Table 44. Teva Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Teva Peptide Therapeutics Drugs Product Portfolio Table 46. Teva Recent Development Table 47. Sanofi Company Information Table 48. Sanofi Business Overview Table 49. Sanofi Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Sanofi Peptide Therapeutics Drugs Product Portfolio Table 51. Sanofi Recent Development Table 52. J & J Company Information Table 53. J & J Business Overview Table 54. J & J Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. J & J Peptide Therapeutics Drugs Product Portfolio Table 56. J & J Recent Development Table 57. Novartis Company Information Table 58. Novartis Business Overview Table 59. Novartis Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Novartis Peptide Therapeutics Drugs Product Portfolio Table 61. Novartis Recent Development Table 62. Novo Nordisk Company Information Table 63. Novo Nordisk Business Overview Table 64. Novo Nordisk Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Novo Nordisk Peptide Therapeutics Drugs Product Portfolio Table 66. Novo Nordisk Recent Development Table 67. Merck Company Information Table 68. Merck Business Overview Table 69. Merck Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Merck Peptide Therapeutics Drugs Product Portfolio Table 71. Merck Recent Development Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Eli Lilly Peptide Therapeutics Drugs Product Portfolio Table 76. Eli Lilly Recent Development Table 77. Ferring Company Information Table 78. Ferring Business Overview Table 79. Ferring Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Ferring Peptide Therapeutics Drugs Product Portfolio Table 81. Ferring Recent Development Table 82. AbbVie Company Information Table 83. AbbVie Business Overview Table 84. AbbVie Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. AbbVie Peptide Therapeutics Drugs Product Portfolio Table 86. AbbVie Recent Development Table 87. AstraZeneca Company Information Table 88. AstraZeneca Business Overview Table 89. AstraZeneca Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. AstraZeneca Peptide Therapeutics Drugs Product Portfolio Table 91. AstraZeneca Recent Development Table 92. The Medicines Company Information Table 93. The Medicines Business Overview Table 94. The Medicines Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. The Medicines Peptide Therapeutics Drugs Product Portfolio Table 96. The Medicines Recent Development Table 97. Lantheus Company Information Table 98. Lantheus Business Overview Table 99. Lantheus Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Lantheus Peptide Therapeutics Drugs Product Portfolio Table 101. Lantheus Recent Development Table 102. Ipsen Company Information Table 103. Ipsen Business Overview Table 104. Ipsen Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Ipsen Peptide Therapeutics Drugs Product Portfolio Table 106. Ipsen Recent Development Table 107. CSL Vifor Group Company Information Table 108. CSL Vifor Group Business Overview Table 109. CSL Vifor Group Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. CSL Vifor Group Peptide Therapeutics Drugs Product Portfolio Table 111. CSL Vifor Group Recent Development Table 112. BioMarin Pharmaceutical Company Information Table 113. BioMarin Pharmaceutical Business Overview Table 114. BioMarin Pharmaceutical Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. BioMarin Pharmaceutical Peptide Therapeutics Drugs Product Portfolio Table 116. BioMarin Pharmaceutical Recent Development Table 117. Aurinia Pharmaceuticals Company Information Table 118. Aurinia Pharmaceuticals Business Overview Table 119. Aurinia Pharmaceuticals Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Aurinia Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio Table 121. Aurinia Pharmaceuticals Recent Development Table 122. Apellis Pharmaceuticals Company Information Table 123. Apellis Pharmaceuticals Business Overview Table 124. Apellis Pharmaceuticals Peptide Therapeutics Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Apellis Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio Table 126. Apellis Pharmaceuticals Recent Development Table 127. North America Peptide Therapeutics Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Peptide Therapeutics Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Peptide Therapeutics Drugs Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Peptide Therapeutics Drugs Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Peptide Therapeutics Drugs Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Peptide Therapeutics Drugs Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Peptide Therapeutics Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Peptide Therapeutics Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Peptide Therapeutics Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Peptide Therapeutics Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Peptide Therapeutics Drugs Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Peptide Therapeutics Drugs Revenue by Country (US$ Million) & (2027-2032) Table 141. China Peptide Therapeutics Drugs Revenue by Type (2021-2026) & (US$ Million) Table 142. China Peptide Therapeutics Drugs Revenue by Type (2027-2032) & (US$ Million) Table 143. China Peptide Therapeutics Drugs Revenue by Application (2021-2026) & (US$ Million) Table 144. China Peptide Therapeutics Drugs Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Peptide Therapeutics Drugs Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Peptide Therapeutics Drugs Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Peptide Therapeutics Drugs Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Peptide Therapeutics Drugs Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Peptide Therapeutics Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Peptide Therapeutics Drugs Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Peptide Therapeutics Drugs Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Peptide Therapeutics Drugs Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Peptide Therapeutics Drugs Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Peptide Therapeutics Drugs Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Peptide Therapeutics Drugs Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Peptide Therapeutics Drugs Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Peptide Therapeutics Drugs Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Peptide Therapeutics Drugs Image Figure 2. Global Peptide Therapeutics Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Therapeutics Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. Oral Image Figure 6. Other Image Figure 7. Global Peptide Therapeutics Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Peptide Therapeutics Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Central Nervous System Image Figure 10. Metabolic Disorders Image Figure 11. Cancer Image Figure 12. Other Image Figure 13. Global Peptide Therapeutics Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Peptide Therapeutics Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Peptide Therapeutics Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Peptide Therapeutics Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Peptide Therapeutics Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Peptide Therapeutics Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Peptide Therapeutics Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Peptide Therapeutics Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Peptide Therapeutics Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Peptide Therapeutics Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Peptide Therapeutics Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Peptide Therapeutics Drugs Revenue Share by Type (2021-2032) Figure 26. North America Peptide Therapeutics Drugs Revenue Share by Application (2021-2032) Figure 27. North America Peptide Therapeutics Drugs Revenue Share by Country (2021-2032) Figure 28. United States Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Peptide Therapeutics Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Peptide Therapeutics Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Peptide Therapeutics Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Peptide Therapeutics Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Peptide Therapeutics Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Peptide Therapeutics Drugs Revenue Share by Type (2021-2032) Figure 45. China Peptide Therapeutics Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Peptide Therapeutics Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Peptide Therapeutics Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Peptide Therapeutics Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Peptide Therapeutics Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Peptide Therapeutics Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Peptide Therapeutics Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Peptide Therapeutics Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Peptide Therapeutics Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Peptide Therapeutics Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
  • Other
Applications
  • Central Nervous System
  • Metabolic Disorders
  • Cancer
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • J & J
  • Novartis
  • Novo Nordisk
  • Merck
  • Eli Lilly
  • Ferring
  • AbbVie
  • AstraZeneca
  • The Medicines
  • Lantheus
  • Ipsen
  • CSL Vifor Group
  • BioMarin Pharmaceutical
  • Aurinia Pharmaceuticals
  • Apellis Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Peptide Therapeutics Drugs Market by Type
  3. 1.2.1 Global Peptide Therapeutics Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Oral
  6. 1.2.4 Other
  7. 1.3 Peptide Therapeutics Drugs Market by Application
  8. 1.3.1 Global Peptide Therapeutics Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Central Nervous System
  10. 1.3.3 Metabolic Disorders
  11. 1.3.4 Cancer
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Peptide Therapeutics Drugs Market Dynamics
  1. 2.1 Peptide Therapeutics Drugs Industry Trends
  2. 2.2 Peptide Therapeutics Drugs Industry Drivers
  3. 2.3 Peptide Therapeutics Drugs Industry Opportunities and Challenges
  4. 2.4 Peptide Therapeutics Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Peptide Therapeutics Drugs Market Perspective (2021-2032)
  2. 3.2 Global Peptide Therapeutics Drugs Growth Trends by Region
  3. 3.2.1 Global Peptide Therapeutics Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Peptide Therapeutics Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Peptide Therapeutics Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Peptide Therapeutics Drugs Revenue by Players
  2. 4.1.1 Global Peptide Therapeutics Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Peptide Therapeutics Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Peptide Therapeutics Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Peptide Therapeutics Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Peptide Therapeutics Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Peptide Therapeutics Drugs Players, Product Type & Application
  8. 4.5 Global Peptide Therapeutics Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Peptide Therapeutics Drugs Market CR5 and HHI
  11. 4.6.3 2025 Peptide Therapeutics Drugs Tier 1, Tier 2, and Tier 3
5 Peptide Therapeutics Drugs Market Size by Type
  1. 5.1 Global Peptide Therapeutics Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Peptide Therapeutics Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Peptide Therapeutics Drugs Revenue Market Share by Type (2021-2032)
6 Peptide Therapeutics Drugs Market Size by Application
  1. 6.1 Global Peptide Therapeutics Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Peptide Therapeutics Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Peptide Therapeutics Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Takeda
  2. 7.1.1 Takeda Company Information
  3. 7.1.2 Takeda Business Overview
  4. 7.1.3 Takeda Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Peptide Therapeutics Drugs Product Portfolio
  6. 7.1.5 Takeda Recent Developments
  7. 7.2 Teva
  8. 7.2.1 Teva Company Information
  9. 7.2.2 Teva Business Overview
  10. 7.2.3 Teva Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Teva Peptide Therapeutics Drugs Product Portfolio
  12. 7.2.5 Teva Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Peptide Therapeutics Drugs Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 J & J
  20. 7.4.1 J & J Company Information
  21. 7.4.2 J & J Business Overview
  22. 7.4.3 J & J Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 J & J Peptide Therapeutics Drugs Product Portfolio
  24. 7.4.5 J & J Recent Developments
  25. 7.5 Novartis
  26. 7.5.1 Novartis Company Information
  27. 7.5.2 Novartis Business Overview
  28. 7.5.3 Novartis Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Novartis Peptide Therapeutics Drugs Product Portfolio
  30. 7.5.5 Novartis Recent Developments
  31. 7.6 Novo Nordisk
  32. 7.6.1 Novo Nordisk Company Information
  33. 7.6.2 Novo Nordisk Business Overview
  34. 7.6.3 Novo Nordisk Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Novo Nordisk Peptide Therapeutics Drugs Product Portfolio
  36. 7.6.5 Novo Nordisk Recent Developments
  37. 7.7 Merck
  38. 7.7.1 Merck Company Information
  39. 7.7.2 Merck Business Overview
  40. 7.7.3 Merck Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Merck Peptide Therapeutics Drugs Product Portfolio
  42. 7.7.5 Merck Recent Developments
  43. 7.8 Eli Lilly
  44. 7.8.1 Eli Lilly Company Information
  45. 7.8.2 Eli Lilly Business Overview
  46. 7.8.3 Eli Lilly Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly Peptide Therapeutics Drugs Product Portfolio
  48. 7.8.5 Eli Lilly Recent Developments
  49. 7.9 Ferring
  50. 7.9.1 Ferring Company Information
  51. 7.9.2 Ferring Business Overview
  52. 7.9.3 Ferring Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ferring Peptide Therapeutics Drugs Product Portfolio
  54. 7.9.5 Ferring Recent Developments
  55. 7.10 AbbVie
  56. 7.10.1 AbbVie Company Information
  57. 7.10.2 AbbVie Business Overview
  58. 7.10.3 AbbVie Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AbbVie Peptide Therapeutics Drugs Product Portfolio
  60. 7.10.5 AbbVie Recent Developments
  61. 7.11 AstraZeneca
  62. 7.11.1 AstraZeneca Company Information
  63. 7.11.2 AstraZeneca Business Overview
  64. 7.11.3 AstraZeneca Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 AstraZeneca Peptide Therapeutics Drugs Product Portfolio
  66. 7.11.5 AstraZeneca Recent Developments
  67. 7.12 The Medicines
  68. 7.12.1 The Medicines Company Information
  69. 7.12.2 The Medicines Business Overview
  70. 7.12.3 The Medicines Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 The Medicines Peptide Therapeutics Drugs Product Portfolio
  72. 7.12.5 The Medicines Recent Developments
  73. 7.13 Lantheus
  74. 7.13.1 Lantheus Company Information
  75. 7.13.2 Lantheus Business Overview
  76. 7.13.3 Lantheus Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Lantheus Peptide Therapeutics Drugs Product Portfolio
  78. 7.13.5 Lantheus Recent Developments
  79. 7.14 Ipsen
  80. 7.14.1 Ipsen Company Information
  81. 7.14.2 Ipsen Business Overview
  82. 7.14.3 Ipsen Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Ipsen Peptide Therapeutics Drugs Product Portfolio
  84. 7.14.5 Ipsen Recent Developments
  85. 7.15 CSL Vifor Group
  86. 7.15.1 CSL Vifor Group Company Information
  87. 7.15.2 CSL Vifor Group Business Overview
  88. 7.15.3 CSL Vifor Group Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 CSL Vifor Group Peptide Therapeutics Drugs Product Portfolio
  90. 7.15.5 CSL Vifor Group Recent Developments
  91. 7.16 BioMarin Pharmaceutical
  92. 7.16.1 BioMarin Pharmaceutical Company Information
  93. 7.16.2 BioMarin Pharmaceutical Business Overview
  94. 7.16.3 BioMarin Pharmaceutical Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 BioMarin Pharmaceutical Peptide Therapeutics Drugs Product Portfolio
  96. 7.16.5 BioMarin Pharmaceutical Recent Developments
  97. 7.17 Aurinia Pharmaceuticals
  98. 7.17.1 Aurinia Pharmaceuticals Company Information
  99. 7.17.2 Aurinia Pharmaceuticals Business Overview
  100. 7.17.3 Aurinia Pharmaceuticals Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Aurinia Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio
  102. 7.17.5 Aurinia Pharmaceuticals Recent Developments
  103. 7.18 Apellis Pharmaceuticals
  104. 7.18.1 Apellis Pharmaceuticals Company Information
  105. 7.18.2 Apellis Pharmaceuticals Business Overview
  106. 7.18.3 Apellis Pharmaceuticals Peptide Therapeutics Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Apellis Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio
  108. 7.18.5 Apellis Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Peptide Therapeutics Drugs Revenue (2021-2032)
  2. 8.2 North America Peptide Therapeutics Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Peptide Therapeutics Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Peptide Therapeutics Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Peptide Therapeutics Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Peptide Therapeutics Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Peptide Therapeutics Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Peptide Therapeutics Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Peptide Therapeutics Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Peptide Therapeutics Drugs Revenue by Country
  11. 8.6.1 North America Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Peptide Therapeutics Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Peptide Therapeutics Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Peptide Therapeutics Drugs Revenue (2021-2032)
  2. 9.2 Europe Peptide Therapeutics Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Peptide Therapeutics Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Peptide Therapeutics Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Peptide Therapeutics Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Peptide Therapeutics Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Peptide Therapeutics Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Peptide Therapeutics Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Peptide Therapeutics Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Peptide Therapeutics Drugs Revenue by Country
  11. 9.6.1 Europe Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Peptide Therapeutics Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Peptide Therapeutics Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Peptide Therapeutics Drugs Revenue (2021-2032)
  2. 10.2 China Peptide Therapeutics Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Peptide Therapeutics Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Peptide Therapeutics Drugs Revenue by Type (2027-2032)
  5. 10.3 China Peptide Therapeutics Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Peptide Therapeutics Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Peptide Therapeutics Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Peptide Therapeutics Drugs Revenue by Application (2027-2032)
  9. 10.5 China Peptide Therapeutics Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Peptide Therapeutics Drugs Revenue (2021-2032)
  2. 11.2 Asia Peptide Therapeutics Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Peptide Therapeutics Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Peptide Therapeutics Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Peptide Therapeutics Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Peptide Therapeutics Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Peptide Therapeutics Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Peptide Therapeutics Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Peptide Therapeutics Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Peptide Therapeutics Drugs Revenue by Country
  11. 11.6.1 Asia Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Peptide Therapeutics Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Peptide Therapeutics Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Peptide Therapeutics Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Peptide Therapeutics Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Peptide Therapeutics Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Peptide Therapeutics Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Peptide Therapeutics Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Peptide Therapeutics Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Peptide Therapeutics Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Peptide Therapeutics Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Peptide Therapeutics Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Peptide Therapeutics Drugs Revenue by Country
  11. 12.6.1 SAMEA Peptide Therapeutics Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Peptide Therapeutics Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Peptide Therapeutics Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst